

Enhance Smooth Muscle Cells Apoptosis Associated With Pulmonary Arterial Remodeling in Dogs Affected With Pulmonary Hypertension Secondary to Degenerative Mitral Valve Disease

Siriwan Sakarin

Department of Veterinary Medicine, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, 10330, Thailand

Anudep Rungsipipat

Companion Animal Cancer Research Unit, Department of Pathology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, 10330, Thailand

Sirilak Disatian Surachetpong (✉ sirilakd27@gmail.com)

Department of Veterinary Medicine, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, 10330, Thailand

Research Article

Keywords: Apoptosis, Degenerative mitral valve disease, Medial thickening, Pulmonary hypertension, Smooth muscle cells

Posted Date: February 2nd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-155698/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **Enhance smooth muscle cells apoptosis associated with pulmonary arterial remodeling in dogs**
2 **affected with pulmonary hypertension secondary to degenerative mitral valve disease**

3

4 Siriwan Sakarin^a, DVM, MS, Anudep Rungsipat^b, DVM, PhD, Sirilak Disatian Surachetpong^{a,*}, DVM,
5 MS, PhD

6

7 ^aDepartment of Veterinary Medicine, Faculty of Veterinary Science, Chulalongkorn University,
8 Bangkok, 10330, Thailand

9 ^bCompanion Animal Cancer Research Unit, Department of Pathology, Faculty of Veterinary Science,
10 Chulalongkorn University, Bangkok, 10330, Thailand

11

12 *Corresponding author: Sirilak Disatian Surachetpong

13 E-mail address: sirilakd27@gmail.com

14

15

16

17

18

19

20

21

22

23

24

25

26 **Abstract**

27 **Background:** Degenerative mitral valve disease (DMVD) is the most common cause of pulmonary
28 hypertension (PH) in dogs. Medial thickening of the pulmonary artery is a major histopathological
29 change in PH. A decrease in apoptosis of pulmonary arterial smooth muscle cells (SMCs) may be the
30 cause of medial thickening. This study aimed to demonstrate the expression of apoptosis molecules
31 in the pulmonary artery of dogs affected with PH secondary to DMVD (DMVD+PH) compared to
32 DMVD without PH (DMVD) and healthy dogs (control). Lung samples were collected from three
33 groups including control (n=5), DMVD (n=7) and DMVD+PH (n=7) groups. Masson trichrome and
34 apoptotic proteins including Bax, Bcl2 and caspase-3 and -8, were stained.

35 **Results:** The medial thickness in the DMVD and DMVD+PH groups was greater than in the control
36 group and it was greatest in the DMVD+PH group. Bax, Bcl2 and caspase-3 and -8 were expressed
37 mainly in the medial layer of the pulmonary artery. The percentages of Bax and caspase-3 and -8
38 positive cells were higher in the DMVD group compared to the DMVD+PH group, whereas the
39 percentage of Bcl2-positive cells was increased in the DMVD and DMVD+PH groups. These findings
40 suggested that apoptosis of pulmonary arterial SMCs occurred mainly in the DMVD group and
41 decreased dramatically in the DMVD+PH group.

42 **Conclusions:** An increase in the medial thickness in dogs affected with PH secondary to DMVD may
43 occur due to a decrease in apoptosis of pulmonary arterial SMCs.

44

45 **Keywords:** Apoptosis, Degenerative mitral valve disease, Medial thickening, Pulmonary
46 hypertension, Smooth muscle cells

47

48 **Background**

49 Pulmonary hypertension (PH) involves a hemodynamic and pathophysiological change in
50 pressure within the pulmonary vasculature. It has been defined as an abnormal increase in
51 pulmonary arterial systolic pressure (PAP). In veterinary medicine, dogs with clinical signs of PH, such

52 as dyspnoea and syncope and an estimated PAP of > 46 mmHg measured by echocardiography, are
53 defined with PH (1).

54 Degenerative mitral valve disease (DMVD) is a left-sided heart disease frequently found in
55 small-sized breed dogs (2), and it is the most common cause of PH in dogs (1, 3). As the disease
56 progresses, the degenerative valve cannot close properly during systole causing mitral valve
57 regurgitation and volume overload in the left atrium. In the advanced stage, some dogs may suffer
58 from left-sided heart failure (4) and/or develop complications such as PH and right-sided heart
59 failure (3, 5-7). DMVD dogs with clinical signs such as syncope, respiratory distress and exercise
60 intolerance are suggestive of PH (1, 7). While right heart catheterisation is a gold-standard method
61 for diagnosing PH in human patients, the suggestive clinical signs of PH and echocardiographic
62 parameters, including estimated PAP and echocardiographic signs of PH involving ventricles,
63 pulmonary artery, right atrium and caudal vena cava, have been used to diagnose PH in dogs (1, 3, 8,
64 9).

65 Pulmonary arterial remodelling is the histopathological changes in the pulmonary artery
66 found in human patients affected with PH and in PH-induced animal models. The histopathological
67 changes affect all layers of the pulmonary arterial wall, including the intimal, medial and adventitial
68 layers (3, 10). The deposition of fibroblasts and connective tissues in the intimal and adventitial
69 layers are referred to as intimal and adventitial fibrosis, respectively (11). Medial remodelling
70 causing medial thickening is a hallmark structural change in the pulmonary artery found in patients
71 affected with PH secondary to several causes, including chronic obstructive pulmonary disease (12),
72 idiopathic PH (13) and left-sided heart failure (14, 15) and in PH-induced animal models (16-20). The
73 aetiology of medial thickening remains unknown. The homeostasis of pulmonary arterial SMC
74 proliferation and apoptosis is essential for maintaining the normal structure of the pulmonary artery,
75 and the imbalance of cell death and proliferation in SMCs may play a role in medial thickening. The
76 decrease in apoptosis of pulmonary arterial SMCs has been suggested as a possible cause of the
77 increased number of SMCs and medial thickness in the pulmonary artery (21).

78 Apoptosis is a complex mechanism that involves two main pathways: intrinsic and extrinsic
79 pathways. The extrinsic pathway is initiated by cells, no longer needed, receiving an external signal,
80 which then transmits from the cell surface to intracellular signal pathways, resulting in activation of
81 caspase-8 and then promoting activation of effector caspase-3. The intrinsic pathway is triggered by
82 stimuli that cause stress or damage to the cell. Intracellular signals cause a change in the
83 mitochondrial membrane leading to the release of cytochrome c to the cytoplasm, forming
84 apoptosomes, cleaving and activating effector caspase-3 (22, 23). Therefore, caspase-3 is an
85 essential effector caspase responsible for extrinsic and intrinsic pathways and causing a breakdown
86 of DNA and chromatin condensation (22, 24). Apart from caspase proteins, cytoplasmic proteins
87 called Bcl2 family proteins, are also associated with the apoptotic pathway. The Bcl2 family proteins
88 can be categorised into two main groups, manifesting pro-apoptotic and anti-apoptotic responses,
89 including pro-apoptotic Bcl2 associated protein (Bax) and anti-apoptotic B-cell lymphoma 2 protein
90 (Bcl2), respectively (22). The ratio of Bax to Bcl2 appears to be the prognostic factor for determining
91 the susceptibility of cells to apoptosis (24).

92 Several studies have suggested that a decrease in apoptosis of pulmonary arterial SMCs is
93 associated with increased medial thickness in human patients and in animal models with PH (25-31).
94 Moreover, induction or stimulation of pulmonary arterial SMCs apoptosis can reverse PAP, restore
95 the pulmonary artery to its normal structure or prevent medial thickening progression (23, 32).
96 However, there is no study investigating the expression of proteins related to apoptosis in the
97 pulmonary artery of dogs affected with PH secondary to DMVD. Therefore, this study aimed to
98 demonstrate the expression of molecules in apoptosis pathways in the pulmonary artery of dogs
99 affected with PH secondary to DMVD compared to DMVD without PH and healthy control dogs.

100

101 **Results**

102 *Clinical characteristics of dogs*

103 The control group consisted of 5 dogs including 3 males (M=1, Mc=2) and 2 females (F=1,
104 Fs=1) with breeds of Shih Tzu (n=3), Mixed and Pomeranian. The DMVD group consisted of 7 dogs
105 including 3 males (M=1, Mc=2) and 4 females (F=2, Fs=2) with breeds of Poodle (n=4), Shih Tzu (n=2)
106 and Pomeranian. The DMVD+PH group consisted of 7 dogs including 4 males (M=2, Mc=2) and 3
107 females (F=2, Fs=1) with breeds of Poodle (n=2), Chihuahua (n=2), Shih Tzu, Pomeranian and
108 Schnauzer. Age and weight of dogs among the control (11.2±3.63 year; 5.59±0.38 kg), DMVD
109 (13.71±1.80 year; 4.91±1.49 kg) and DMVD+PH (13.86±1.57 year; 6.25±2.99 kg) groups were not
110 significantly different (p=0.136, 0.486). Sex among groups were approximately the same. Almost all
111 of dogs in the DMVD and DMVD+PH group were died from cardiovascular failure. Only one dogs in
112 the DMVD+PH group was euthanized due to unresponsive to the standard therapy. Dogs in the
113 control group were died secondary to postoperative complication and car accident. The average
114 estimated PAP of dogs in the DMVD+PH group was 75.77 ± 28.79 mmHg (range 49.51-116 mmHg).


115

116 *Pulmonary arterial remodeling*

117 The main histopathological changes of lung in the DMVD and DMVD+PH groups were
118 congestion and pulmonary edema. Masson trichrome staining showed interstitial alveolar fibrosis in
119 some dogs in the DMVD+PH group (2 of 7 dogs). Microscopic examination of pulmonary arteries
120 showed thin medial layer in the control group, whereas multiple layers of SMCs in the medial layer
121 was presented in all dogs in the DMVD and DMVD+PH groups (Fig.1).

122

123



124

125 **Figure 1: The histopathology of the pulmonary artery**

126 Masson's trichrome staining revealed normal thin medial layer in the control group (a) and increased medial
 127 thickness in the degenerative mitral valve disease (DMVD) (b) and degenerative mitral valve disease with
 128 pulmonary hypertension (DMVD+PH) (c) groups. Red color are staining of SMCs; Blue color are staining of
 129 collagen fibers (Masson's trichrome stain, 100x magnification).

130

131 The percentage of medial thickness (%MT) was significantly increased in the DMVD and
 132 DMVD+PH groups compared to the control group ($p < 0.0001$). Moreover, dogs in the DMVD+PH
 133 group had %MT greater than those in the DMVD group ($p < 0.0001$) (Table1, Fig.2). The average
 134 number in the DMVD and DMVD+PH groups were significantly increased compared to the control
 135 group and it was highest in the DMVD+PH group (Table1, Fig.2). The percentage of medial thickness
 136 showed strong correlation with the average number of SMCs ($r = 0.894$, $p < 0.0001$).

137

138

139

140

141


142

143

144

145

146



147

148 **Figure 2: The percentage of medial thickness and the average number of pulmonary arterial SMCs per**
 149 **vessel.**

150 The graphs show the percentage of medial thickness (%MT) (a) and the average number of pulmonary arterial
 151 SMCs per vessel (b) of the control, degenerative mitral valve disease (DMVD) and degenerative mitral valve
 152 disease with pulmonary hypertension (DMVD+PH) groups. Data are expressed as mean and standard deviation
 153 (SD) (bars). An increase in %MT in the DMVD and DMVD+PH groups conforms to an increase in the average
 154 number of pulmonary arterial SMCs.

155 ^a Indicate statistically significant difference at $p < 0.05$ compared to the control group.

156 ^{b,c} Indicate statistically significant difference at $p < 0.05$ between the DMVD and DMVD+PH groups.

157

158

159 **Table 1** The percentage of medial thickness and the average number of pulmonary arterial SMCs per
 160 vessel

Parameter	Control (n=5)	DMVD (n=7)	DMVD+PH (n=7)	p-value
%MT	11.04 ± 0.95	22.36 ± 1.44 ^{a, b}	32.25 ± 5.06 ^{a, c}	^a <0.0001 ^{b, c} <0.0001
SMCs (cells)	29.04 ± 2.15	51.65 ± 4.11 ^{a, b}	69.53 ± 8.33 ^{a, c}	^a <0.0001 ^{b, c} <0.0001

161 Data are expressed as mean \pm standard deviation (SD).

162 The significant difference was assessed by one-way ANOVA at $p < 0.05$.


163 ^a Indicate significant difference at $p < 0.05$ compared to the control group.

164 ^{b, c} Indicate significant difference at $p < 0.05$ between the DMVD and DMVD+PH groups.

165

166 *Expression of proteins associated with apoptosis pathways*


167 Immunohistochemistry was performed to localize proteins associated with apoptosis
168 pathways including Bax (pro-apoptotic protein), Bcl2 (anti-apoptotic protein), caspase-3 and
169 caspase-8 (caspase proteins). The results showed that Bax, Bcl2, caspase-3 and caspase-8 were
170 mainly expressed in medial layers of pulmonary arteries (Fig.3,4).



171

172 **Figure 3: Immunohistochemical expression of Bax and Bcl2 in pulmonary arteries.**

173 The images shows the expression of Bax and Bcl2 in the pulmonary arteries of the control (a, d), degenerative
174 mitral valve disease (DMVD) (b, e) and degenerative mitral valve disease with pulmonary hypertension
175 (DMVD+PH) groups (c, f). These proteins were mainly expressed in SMCs located at medial layer of pulmonary
176 artery. Bax protein was stained in all groups, whereas Bcl2 protein was not stained in the control group. The
177 intracytoplasmic staining of Bax and intranuclear staining of Bcl2 in pulmonary arterial SMCs presented as
178 brown color (Labeled streptavidin-biotin, Immunohistochemistry, Mayer's Hematoxylin counterstained, 400x
179 magnification).




180

181 **Figure 4: Immunohistochemical expression of caspase-3 and -8 in pulmonary arteries.**

182 The images show the expression of caspase-3 and -8 in the pulmonary arteries of the control (a, d),
 183 degenerative mitral valve disease (DMVD) (b, e) and degenerative mitral valve disease with pulmonary
 184 hypertension (DMVD+PH) groups (c, f). The caspase-3 and -8 expressions were mainly found in SMCs located
 185 at the medial layer of the pulmonary artery in all 3 groups. The intracytoplasmic and intranuclear staining of
 186 caspase-3 and intracytoplasmic staining of caspase-8 were in brown color. (Labeled streptavidin-biotin,
 187 Immunohistochemistry, Mayer's Hematoxylin counterstained, 400x magnification).

188

189 Intracytoplasmic staining of Bax was detected in SMCs located in the medial layer of dogs in
 190 the control, DMVD and DMVD+PH groups (Fig.3). The percentage of Bax positive cells in the DMVD
 191 and DMVD+PH groups were higher than the control group ($p < 0.0001$). However, it was decreased in
 192 the DMVD+PH group compared to the DMVD group ($p < 0.0001$) (Table2, Fig.5). Intranuclear Bcl2
 193 expression was found only in DMVD dogs with and without PH but not in control dogs (Fig.3).
 194 Contrary to Bax, Bcl2 expression was very low in the DMVD group and significantly increased in the
 195 DMVD+PH group ($p < 0.0001$) (Table2, Fig.5). The Bax to Bcl2 ratio was high in the DMVD group and
 196 dramatically reduced in the DMVD+PH group ($p < 0.0001$) (Table2, Fig.5).



197

198 **Figure 5: The percentage of Bax, Bcl2, and caspase-3 and -8 positive cells and Bax/Bcl2 ratio**

199 The graph show the percentage of Bax, Bcl2, and caspase-3 and -8 positive cells and Bax/Bcl2 ratio of the
 200 control, degenerative mitral valve disease (DMVD) and degenerative mitral valve disease with pulmonary
 201 hypertension (DMVD+PH) groups. Data are expressed as mean and standard deviation (SD) (bars). The
 202 percentage of Bax and caspase-3 and -8 positive cells as well as Bax/Bcl2 ratio were highest in the DMVD
 203 group, opposite to the percentage of Bcl2 positive cells that was highest in the DMVD+PH group.

204 ^a Indicate statistically significant difference at $p < 0.05$ compared to the control group.

205 ^{b,c} Indicate statistically significant difference at $p < 0.05$ between the DMVD and DMVD+PH groups.

206

207 As for downstream signaling proteins, caspase-3 and caspase-8 proteins were stained in
 208 pulmonary arterial SMCs of dogs in all 3 groups. Caspase-3 was expressed in the nucleus and
 209 cytoplasm, whereas caspase-8 was expressed only in the cytoplasm of pulmonary arterial SMCs
 210 (Fig.4). The percentage of caspase-3 and caspase-8 positive cells was highest in the DMVD group
 211 compared to the control and DMVD+PH groups. Interestingly, %caspase-3 positive cells was very low
 212 in the DMVD+PH groups and lower than the control group. However, %caspase-8 positive cells in the
 213 DMVD+PH group was higher than the control group (Table2, Fig.5).

214

215

216

217

218 **Table 2** The percentage of Bax, Bcl2 and caspase-3 and -8 positive cells and Bax/Bcl2 ratio

Parameter	Control (n=5)	DMVD (n=7)	DMVD+PH (n=7)	p-value
%Bax	5.32 ± 1.36	90.13 ± 2.08 ^{a, b}	47.69 ± 2.61 ^{a, c}	^a <0.0001 ^{b, c} <0.0001
%Bcl2	0	3.16 ± 1.24 ^{a, b}	22.65 ± 3.00 ^{a, c}	^a <0.0001 ^{b, c} <0.0001
%Caspase-3	22.05 ± 4.13	31.42 ± 3.86 ^{a, b}	9.88 ± 2.81 ^{a, c}	^a <0.0001 ^{b, c} <0.0001
%Caspase-8	11.51 ± 0.61	45.78 ± 1.85 ^{a, b}	35.73 ± 2.77 ^{a, c}	^a <0.0001 ^{b, c} <0.0001
Bax/Bcl2 ratio	-	31.97 ± 10.86 ^b	2.12 ± 0.19 ^c	^{b, c} <0.0001

219 Data are expressed as mean ± standard deviation (SD).

220 The significant difference of %Bax, %Bcl2, %caspase-3 and %caspase-8 were assessed by one-way
221 ANOVA at p < 0.05.

222 The significant difference of Bax/Bcl2 ratio was assessed by independent t-test at p < 0.05.

223 ^a Indicate significant difference at p < 0.05 compared to the control group.

224 ^{b, c} Indicate significant difference at p < 0.05 between the DMVD and DMVD+PH groups.

225

226 The percentage of medial thickness and the average number of pulmonary arterial SMCs per
227 area showed a similar correlation pattern with apoptosis associated proteins. The percentage of Bcl2
228 positive cells was positively correlated with %MT (r=0.829, p<0.0001) and the average number of
229 pulmonary arterial SMCs per area (r=0.867, p<0.0001). The percentage of caspase-3 positive cells
230 was negatively correlated with %MT (r=-0.498, p=0.03) and the average number of pulmonary
231 arterial SMCs per area (r=-0.466, p=0.044).

232

233 **Discussion**

234 The aim of this study was to determine whether or not the apoptosis resistance of
235 pulmonary arterial SMCs was associated with medial thickening in the dogs affected with PH
236 secondary to DMVD or not. The results of the study suggested that apoptosis of pulmonary arterial
237 SMCs was dramatically decreased in the DMVD+PH group.

238 The main histopathological changes in the lungs in DMVD and DMVD+PH groups were
239 pulmonary oedema and congestion, which is consistent with the results from a previous study that
240 examined pulmonary histopathology from a surgical biopsy of the lungs of DMVD dogs (33).
241 Interestingly, some dogs in the DMVD+PH group showed alveolar fibrosis, which is characterised by
242 increased collagen fibres and reactive fibroblasts in the alveolar septum and usually occurs
243 secondary to lower respiratory tract injury (34-36). Chronic increased hydrostatic forces in the
244 pulmonary capillary bed in dogs with left-sided heart failure dogs can cause damage to the alveolar
245 and interstitial structure, and the healing process forms a scar tissue and fibrosis (33).

246 Medial thickening is a hallmark structural change in the pulmonary artery found in human
247 patients with PH secondary to several causes (12-14, 37) as well as in PH- induced animal models
248 (16-18). The present study revealed that %MT was increased in the DMVD and DMVD+PH groups
249 compared to the control group. Similar findings have been reported in human patients affected with
250 left-sided heart failure both with and without PH (14). Interestingly, %MT in the DMVD group was
251 higher than in the DMVD+PH group. These findings suggest that increased medial thickness could
252 occur even in DMVD dogs without PH and progress continually in DMVD dogs with PH.

253 The cause of medial thickening in subjects affected with PH is not yet completely understood
254 (38, 39). An increase in the number of pulmonary arterial SMCs may be one of the causes of medial
255 thickening. The present study showed that the total number of pulmonary arterial SMCs was
256 significantly increased in the DMVD and DMVD+PH groups compared to the control group, was
257 significantly higher in the DMVD+PH group than those in the DMVD group. In addition, a positive
258 correlation was found between the total number of pulmonary arterial SMCs and %MT, suggesting

259 that an increase in the number of pulmonary arterial SMCs probably contributes to medial
260 thickening in DMVD dogs both with and without PH.

261 An increase in the number of pulmonary artery SMCs may occur secondary to the lack of
262 apoptosis (21, 23) (20, 29, 31, 40-42). Apoptosis is a mechanism that maintains the homeostasis of
263 tissues by eliminating unwanted cells. Several proteins are involved in apoptotic pathways, including
264 Bax, Bcl2 and caspase-3 and -8. Bcl2 blocks apoptosis, whereas Bax promotes it. Caspase-3 and -8
265 are important caspases associated with intrinsic and extrinsic apoptotic pathways (24). Several
266 studies have determined the expression of these proteins to evaluate cell apoptosis in several
267 diseases and conditions, including PH (24-30, 43, 44). To the authors' knowledge, this study is the
268 first to evaluate the expression of proteins associated with apoptosis pathways in the pulmonary
269 arteries of dogs affected with PH secondary to DMVD. The results of the study showed that Bax, Bcl2
270 and caspase-3 and -8 are expressed in SMCs in the medial layer of pulmonary arteries in a similar
271 way to that found in humans (29) and animal models (25-28, 30, 44) with PH.

272 Bax, a pro-apoptotic protein, was found in all three groups, whereas Bcl-2, an anti-apoptotic
273 protein, was not found in the control group. The percentage of Bax positive cells (%Bax) was very
274 low in the control group, suggesting that an apoptotic process could be found in normal conditions
275 to limit the number of cells in the pulmonary arterial wall (23). % Bax was increased markedly in the
276 DMVD dogs compared to the normal dogs; however, it was decreased in the DMVD+PH group
277 compared to that in the DMVD group, indicating that apoptosis of pulmonary arterial SMCs occurred
278 mainly in the DMVD group and was reduced in the DMVD+PH group. This finding was in agreement
279 with previous studies in animal models that demonstrated a decrease or absence of Bax expression
280 in the pulmonary arteries of subjects with PH compared to the controls (25-28).

281 The expression of Bcl2, an anti-apoptotic protein, was higher in the DMVD+PH group
282 compared to the other groups. The percentage of Bcl2 positive cells (%Bcl2) was very low in the
283 DMVD group and significantly increased in the DMVD+PH group, which is consistent with studies in
284 animal models (25-28). The results suggest that apoptosis resistance occurred mainly in the

285 pulmonary arterial SMCs of the DMVD dogs with PH. The Bax to Bcl2 ratio can be used to estimate
286 the apoptotic susceptibility of cells: cells with high Bax to Bcl2 ratio are more prone to apoptosis
287 (24, 30). This ratio was decreased in the DMVD+PH group compared to the DMVD group, indicating
288 that the susceptibility to apoptosis was decreased in the DMVD+PH group compared to the DMVD
289 group.

290 The expression of caspase-3 and -8, pro-apoptotic proteins, was correlated with the
291 apoptotic rate. A higher expression of caspase-3 and -8 suggests more apoptosis (45). Caspase-3 is an
292 effector protein related to the extrinsic and intrinsic pathways of apoptosis, whereas caspase-8 is an
293 initiator protein responsible for an extrinsic apoptotic pathway of apoptosis (22, 24). Although
294 caspase-3 expression has been used to evaluate apoptosis in several diseases and conditions
295 including PH, no study has investigated the expression of caspase-8 in subjects suffering from PH.
296 The present study selected caspase-3 and -8 for this study to determine whether intrinsic or extrinsic
297 pathways or both are involved in apoptosis in DMVD dogs with PH. The expression of caspase-3
298 and -8 was found in the medial layer of pulmonary arteries in the three groups, but The percentage
299 of caspase-3 and -8 positive cells (%caspase-3, %caspase-8) were highest in the DMVD group
300 compared to the control and the DMVD+PH groups. Taken together with the results for Bax and
301 Bcl2, it appeared that apoptosis of pulmonary arterial SMCs occurred mainly in the DMVD group and
302 was dramatically decreased in the DMVD+PH group. Interestingly, %caspase-3 in the DMVD+PH
303 group was lower than in the control group, similar to the study in PH-induced animal models (25,
304 27), whereas %caspase-8 in the DMVD+PH group was higher than that in the control group.
305 Moreover, %MT and the number of pulmonary artery SMCs did not correlate with %caspase-8 was
306 negatively correlated with %caspase-3. These findings suggest that the major pathway involved in
307 the apoptosis resistance in DMVD dogs with PH may be an intrinsic, not an extrinsic, pathway.
308 Despite apoptosis occurring mainly in DMVD dogs, they also presented with medial thickening.
309 Therefore, medial thickening in the DMVD dogs may not be caused by a decrease in apoptosis but
310 may be caused by an increase in pulmonary arterial SMCs proliferation.

311 The present study has limitations that need to be addressed. A Terminal deoxynucleotidyl
312 transferase-mediated deoxyuridine triphosphate nick-end labelling (TUNEL) assay was not performed
313 to detect DNA strand breaks in apoptotic cells. However, the immunohistochemical staining of Bax,
314 Bcl2 and caspase-3 and -8 has been widely used to evaluate apoptosis in several diseases and
315 conditions, including PH in human patients and animal models (24-31), and the detection of
316 activating caspase-3 is reflects the induction of cell death by apoptosis. Therefore, the expression of
317 these proteins is sufficient for evaluating apoptosis in the cells. In addition, commercial antibodies
318 against dogs of canine Bax, Bcl2 and caspase-3 and-8 are not available. So, this study used antibodies
319 against human Bax, Bcl2 and caspase-3 and-8 instead of dogs. According to the amino acid sequence
320 of these proteins provided by Uniprot, canine Bax, Bcl2 and caspase-3 and -8 are highly homologous
321 (>80%) to those of humans. Therefore, these antibodies were probably suitable for use in this study.

322

323 **Conclusion**

324 In conclusion, an increase in the medial thickness of the pulmonary artery in DMVD dogs
325 with PH may be partly because of a decrease in apoptosis or the resistance to apoptosis of
326 pulmonary arterial SMCs. This study leads to a better understanding of the pathogenesis of PH in
327 DMVD dogs and the results of this study could have a considerable impact in the future on
328 apoptosis-based therapy to treat or prevent pulmonary arterial remodeling in PH dogs secondary to
329 DMVD in the future.

330

331 **Methods**

332 **Tissue samples**

333 Lung samples were obtained from 19 carcasses of ageing small-sized breed dogs presenting
334 at Department of Veterinary Pathology, Faculty of Veterinary Science, Chulalongkorn University for
335 necropsy. Dogs with pulmonary diseases, heartworm infection, systemic hypertension, neoplasia or
336 other systemic diseases such as kidney and liver diseases determined by antemortem diagnostic

337 records and gross pathology were excluded from this study. All samples were divided into three
338 groups, including control (n=5), degenerative mitral valve disease (DMVD) (n=7) and DMVD with
339 pulmonary hypertension (DMVD+PH) (n=7) based on antemortem diagnostic history and mitral valve
340 thickness evaluated at necropsy. To be included to the control group, dogs had to have normal blood
341 profile values and a mitral valve thickness of < 2 mm measured by a Vernier caliper (46, 47). DMVD
342 dogs were dogs those that had been diagnosed as DMVD stage C (vertebral heart score more than
343 10.5 with current or past radiographic signs of pulmonary edema, left atrial and left ventricle
344 enlargement [$LA/Ao \geq 1.6$ (Swedish method) and left ventricular internal diameter during diastole
345 normalized with Allometric scale method ($LVIDdN \geq 1.7$ assessed by echocardiography before died)
346 (48) and had a mitral valve thickness of > 2 mm at necropsy. DMVD dogs without PH were included
347 in the DMVD group. To be included into DMVD+PH group, DMVD dogs had to have an intermediate-
348 to-high probability of PH secondary to DMVD evaluated by estimated PAP and anatomic structural
349 changes assessed by echocardiography (1, 8).

350 **Immunohistochemistry**

351 Lung tissues were collected from the peripheral regions of right caudal lung lobes and fixed
352 in 10% formalin for 24 hours and embedded in paraffin blocks. Four-micrometre thick lung tissue
353 sections were stained with Masson trichrome for examination of medial thickness. The
354 immunohistochemical staining was performed to evaluate proteins associated with apoptosis
355 pathways including Bax (pro-apoptosis protein), Bcl2 (anti-apoptosis protein) and caspase-3 and
356 caspase-8 following the protocols described previously (24, 26-30, 43, 44, 49). Briefly, lung tissue
357 sections were deparaffinized in xylene, rehydrated in graded alcohol, pretreated with citrate buffer
358 (0.01M, pH 6.0), blocked endogenous peroxidase activity and nonspecific binding by 3% hydrogen
359 peroxide and 1% bovine serum albumin, respectively. Lung tissue sections were then incubated with
360 primary antibodies including polyclonal rabbit anti-Bax (1:100) (A3533, Dako, Glostrup, Denmark),
361 monoclonal mouse anti-Bcl2 (1:100) (NCL-bcl-2-486, Leica Biosystems, Newcastle, UK), rabbit
362 polyclonal anti-caspase-3 (1:100) and caspase-8 (1:100) (ab4051, ab4052, Abcam, Cambridge, UK)

363 overnight. After that lung tissue sections were incubated with horse radish peroxidase-labeled
364 polymer conjugated with secondary antibody followed by 3,3'-diaminobenzidine tetrahydrochloride
365 for visualizing peroxidase activity (Envision Detection System, Peroxidase/DAB, Rabbit/Mouse, Dako,
366 Hamburg, Germany). Finally, lung tissue sections were counterstained with Mayer's hematoxylin.

367 Ten pulmonary arteries with external diameter of approximately 300 μm examined by light
368 microscopy were photographed randomly for each dog with a photomicroscope (Olympus BX50,
369 Olympus Optical, Tokyo, Japan) at 100x magnification to evaluate the percentage of medial thickness
370 (%MT) by measuring the internal and external diameters. The percentage of the medial thickness
371 was calculated by the following equation: $(\text{external diameter} - \text{internal diameter}) / \text{external diameter}$
372 $\times 100$ (17, 18). The 10 pulmonary arteries were photographed at 400x magnification at five per each
373 pulmonary artery. The number of pulmonary arterial SMCs per 400x field were then counted and
374 averaged. The number of cells positive for Bax, Bcl2 and caspase-3 and caspase-8 were counted and
375 calculated as percentage of positive cells per total cell count, and the Bax/Bcl2 ratio was calculated
376 by dividing the percentage of Bax-positive cells by the percentage of Bcl2-positive cells.

377 **Statistical analysis**

378 Statistical analysis was performed by a computer-based software (SPSS, IBM, Chicago, IL,
379 USA). The normality test was evaluated by using the Shapiro-Wilk test. Data were expressed as mean
380 \pm standard deviation (SD). The differences among the control, DMVD and DMVD+PH groups were
381 tested with one-way ANOVA. Bonferroni test was used for post hoc analysis. The p-value for pairwise
382 comparison was adjusted by Bonferroni correction. An independent T-test was used for analyzing
383 the difference of Bax/Bcl2 ratio between the DMVD and DMVD+PH groups. The correlations
384 between %MT, the average number of pulmonary arterial SMCs and proteins associated with
385 apoptosis pathways were evaluated by Pearson's correlation. P-value <0.05 is considered to be
386 statistically significant.

387

388

389 **List of abbreviations**

390	DMVD	Degenerative mitral valve disease
391	LA/Ao	Left atrium to aorta ratio
392	LVIDdn	Left ventricular internal diameter during diastole
393	%MT	Percentage of medial thickness
394	PAP	Pulmonary arterial pressure
395	PH	Pulmonary hypertension
396	RHC	Right heart catheterization
397	SD	Standard deviation
398	SMCs	Smooth muscle cells

399

400 **Declarations**

401 **Ethics approval and consent to participate**

402 This study collected tissue samples from the carcasses of client owned dogs that their owner
403 donated for necropsy and pathological study at Department of Veterinary Pathology, Faculty of
404 Veterinary Science, Chulalongkorn University. An Informed consent form has been signed by the
405 owners.

406 **Consent for publication**

407 Not applicable

408 **Availability of data and materials**

409 All data generated or analysed during this study are included in this published article.

410

411

412

413

414

415 **Competing interests**

416 The authors declare that they have no competing interests

417 **Funding**

418 This study was supported by the 90th Anniversary of Chulalongkorn University Fund
419 (Ratchadaphiseksomphot Endowment Fund), the 100th Anniversary Chulalongkorn University Fund
420 for Doctoral Scholarship and the Thailand Research Fund (RSA 6080009).

421 **Authors' contributions**

422 SDS designed the study. SS performed sample collection and immunohistochemistry. AR
423 performed the histopathological examination. AR, SDS and SS analysed and interpreted data. All
424 authors read and approved the final manuscript.

425 **Acknowledgements**

426 The authors would like to thank all staff at Department of Pathology, Faculty of Veterinary
427 Science, Chulalongkorn University for their helps in sample collection and laboratory facility support.

428 **Authors' information**

429

430 **References**

- 431 1. Reiner C, Visser LC, Kellihan HB, Masseau I, Rozanski E, Clercx C, et al. ACVIM consensus
432 statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary
433 hypertension in dogs. *J Vet Intern Med.* 2020;34:549-73.
- 434 2. Borgarelli M, Buchanan JW. Historical review, epidemiology and natural history of
435 degenerative mitral valve disease. *J Vet Cardiol.* 2012;14(1):93-101.
- 436 3. Kellihan HB, Stepien RL. Pulmonary hypertension in dogs: diagnosis and therapy. *Vet Clin*
437 *North Am Small Anim Pract.* 2010;40(4):623-41.
- 438 4. Fox PR. Pathology of myxomatous mitral valve disease in the dog. *J Vet Cardiol.*
439 2012;14(1):103-26.
- 440 5. Chiavegato D, Borgarelli M, D'Agnolo G, Santilli RA. Pulmonary hypertension in dogs with
441 mitral regurgitation attributable to myxomatous valve disease. *Vet Radiol Ultrasound.*
442 2009;50(3):253-8.
- 443 6. Kim H-T, Han S-M, Song W-J, Kim B, Choi M, Yoon J, et al. Retrospective study of
444 degenerative mitral valve disease in small-breed dogs: Survival and prognostic variables. *J Vet Sci.*
445 2017;18(3):369-76.
- 446 7. Kellihan HB, Stepien RL. Pulmonary hypertension in canine degenerative mitral valve
447 disease. *J Vet Cardiol.* 2012;14(1):149-64.

- 448 8. Borgarelli M, Abbott J, Braz-Ruivo L, Chiavegato D, Crosara S, Lamb K, et al. Prevalence and
449 prognostic importance of pulmonary hypertension in dogs with myxomatous mitral valve disease. *J*
450 *Vet Intern Med.* 2015;29(2):569-74.
- 451 9. Soydan LC, Kellihan HB, Bates ML, Stepien RL, Consigny DW, Bellofiore A, et al. Accuracy of
452 Doppler echocardiographic estimates of pulmonary artery pressures in a canine model of pulmonary
453 hypertension. *J Vet Cardiol.* 2015;17(1):13-24.
- 454 10. Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart
455 failure: the role of the endothelium in pathophysiology and management. *Circulation.*
456 2000;102(14):1718-23.
- 457 11. Guignabert C, Dorfmüller P. Pathology and pathobiology of pulmonary hypertension. *Semin*
458 *Respir Crit Care Med.* 2013;34(5):551-9.
- 459 12. Muñoz-Esquerre M, López-Sánchez M, Escobar I, Huertas D, Penín R, Molina-Molina M, et al.
460 Systemic and pulmonary vascular remodelling in chronic obstructive pulmonary disease. *PLOS ONE.*
461 2016;11(4):e0152987.
- 462 13. Savai R, Pullamsetti SS, Kolbe J, Bieniek E, Voswinckel R, Fink L, et al. Immune and
463 inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. *Am J*
464 *Respir Crit Care Med.* 2012;186(9):897-908.
- 465 14. Delgado JF, Conde E, Sanchez V, Lopez-Rios F, Gomez-Sanchez MA, Escibano P, et al.
466 Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. *Eur J Heart*
467 *Fail.* 2005;7(6):1011-6.
- 468 15. Gerges C, Gerges M, Lang MB, Zhang Y, Jakowitsch J, Probst P, et al. Diastolic pulmonary
469 vascular pressure gradient: a predictor of prognosis in "out-of-proportion" pulmonary hypertension.
470 *Chest.* 2013;143(3):758-66.
- 471 16. Yang PS, Kim DH, Lee YJ, Lee SE, Kang WJ, Chang HJ, et al. Glycyrrhizin, inhibitor of high
472 mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular
473 remodeling in rats. *Respir Res.* 2014;15:148.
- 474 17. Liu M, Wang Y, Wang HM, Bai Y, Zhang XH, Sun YX, et al. Fluoxetine attenuates chronic
475 methamphetamine-induced pulmonary arterial remodeling: possible involvement of serotonin
476 transporter and serotonin 1B receptor. *Basic Clin Pharmacol Toxicol.* 2013;112(2):77-82.
- 477 18. Bai Y, Wang H-M, Liu M, Wang Y, Lian G-C, Zhang X-H, et al. 4-Chloro-DL-phenylalanine
478 protects against monocrotaline-induced pulmonary vascular remodeling and lung inflammation. *Int J*
479 *Mol Med.* 2014;33(2):373-82.
- 480 19. Wang HM, Wang Y, Liu M, Bai Y, Zhang XH, Sun YX, et al. Fluoxetine inhibits monocrotaline-
481 induced pulmonary arterial remodeling involved in inhibition of RhoA-Rho kinase and Akt signalling
482 pathways in rats. *Can J Physiol Pharmacol.* 2012;90(11):1506-15.
- 483 20. Zhai FG, Zhang XH, Wang HL. Fluoxetine protects against monocrotaline-induced pulmonary
484 arterial hypertension: potential roles of induction of apoptosis and upregulation of Kv1.5 channels in
485 rats. *Clin Exp Pharmacol Physiol.* 2009;36(8):850-6.
- 486 21. Jin Y, Choi AMK. Cross talk between autophagy and apoptosis in pulmonary hypertension.
487 *Pulm Circ.* 2012;2(4):407-14.
- 488 22. Elmore S. Apoptosis: a review of programmed cell death. *Toxicol Pathol.* 2007;35(4):495-
489 516.
- 490 23. Gurbanov E, Shiliang X. The key role of apoptosis in the pathogenesis and treatment of
491 pulmonary hypertension. *Eur J Cardiothorac Surg.* 2006;30:499-507.
- 492 24. Salakou S, Kardamakis D, Tsamandas AC, Zolota V, Apostolakis E, Tzelepi V, et al. Increased
493 Bax/Bcl-2 ratio up-regulates caspase-3 and increases apoptosis in the thymus of patients with
494 myasthenia gravis. *In Vivo.* 2007;21(1):123-32.
- 495 25. Chen J, Wang Y-X, Dong M-Q, Zhang B, Luo Y, Niu W, et al. Reoxygenation reverses hypoxic
496 pulmonary arterial remodeling by inducing smooth muscle cell apoptosis via reactive oxygen species-
497 mediated mitochondrial dysfunction. *J Am Heart Assoc.* 2017;6(6):e005602.

- 498 26. Huang X, Zou L, Yu X, Chen M, Guo R, Cai H, et al. Salidroside attenuates chronic hypoxia-
499 induced pulmonary hypertension via adenosine A2a receptor related mitochondria-dependent
500 apoptosis pathway. *J Mol Cell Cardiol.* 2015;82:153-66.
- 501 27. Zhu N, Zhao X, Xiang Y, Ye S, Huang J, Hu W, et al. Thymoquinone attenuates monocrotaline-
502 induced pulmonary artery hypertension via inhibiting pulmonary arterial remodeling in rats. *Int J*
503 *Cardiol.* 2016;221:587-96.
- 504 28. Wang H-L, Peng L-P, Chen W-J, Tang S-H, Sun B-Z, Wang C-L, et al. HMGB1 enhances smooth
505 muscle cell proliferation and migration in pulmonary artery remodeling. *Int J Clin Exp Pathol.*
506 2014;7(7):3836-44.
- 507 29. Chen C, Chen C, Wang Z, Wang L, Yang L, Ding M, et al. Puerarin induces mitochondria-
508 dependent apoptosis in hypoxic human pulmonary arterial smooth muscle cells. *PLOS ONE.*
509 2012;7(3):e34181.
- 510 30. Qiao L, Xie L, Shi K, Zhou T, Hua Y, Liu H. Notch signaling change in pulmonary vascular
511 remodeling in rats with pulmonary hypertension and its implication for therapeutic intervention.
512 *PLOS ONE.* 2012;7(12):e51514.
- 513 31. Guibert C, Marthan R, Savineau JP. Modulation of ion channels in pulmonary arterial
514 hypertension. *Curr Pharm Des.* 2007;13(24):2443-55.
- 515 32. Suzuki YJ, Ibrahim YF, Shults NV. Apoptosis-based therapy to treat pulmonary arterial
516 hypertension. *J Rare Dis Res Treat.* 2016;1(2):17-24.
- 517 33. Lee J, Mizuno M, Mizuno T, Harada K, Uechi M. Pathologic manifestations on surgical biopsy
518 and their correlation with clinical indices in dogs with degenerative mitral valve disease. *J Vet Intern*
519 *Med.* 2015;29(5):1313-21.
- 520 34. Lobetti RG, Milner R, Lane E. Chronic idiopathic pulmonary fibrosis in five dogs. *J Am Anim*
521 *Hosp Assoc.* 2001;37(2):119-27.
- 522 35. Norris CR, Griffey SM, Walsh P. Use of keyhole lung biopsy for diagnosis of interstitial lung
523 diseases in dogs and cats: 13 cases (1998-2001). *J Am Vet Med Assoc.* 2002;221(10):1453-9.
- 524 36. Laurila HP. Canine idiopathic pulmonary fibrosis: Clinical disease, biomarkers and
525 histopathological features: University of Helsinki; 2015.
- 526 37. Chazova I, Robbins I, Loyd J, Newman J, Tapson V, Zhdaov V, et al. Venous and arterial
527 changes in pulmonary veno-occlusive disease, mitral stenosis and fibrosing mediastinitis. *Eur Respir*
528 *J.* 2000;15(1):116-22.
- 529 38. MacLean MR. Pulmonary hypertension and the serotonin hypothesis: where are we now? *Int*
530 *J Clin Pract Suppl.* 2007;156:27-31.
- 531 39. Guazzi M, Arena R. Pulmonary hypertension with left-sided heart disease. *Nat Rev Cardiol.*
532 2010;7(11):648-59.
- 533 40. Zhang S, Fantozzi I, Tigno DD, Yi ES, Platoshyn O, Thistlethwaite PA, et al. Bone
534 morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. *Am J*
535 *Physiol Lung Cell Mol Physiol.* 2003;285(3):L740-54.
- 536 41. McMurtry MS, Bonnet S, Wu X, Dyck JRB, Haromy A, Hashimoto K, et al. Dichloroacetate
537 prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell
538 apoptosis. *Circ Res.* 2004;95(8):830-40.
- 539 42. Lagna G, Nguyen PH, Ni W, Hata A. BMP-dependent activation of caspase-9 and caspase-8
540 mediates apoptosis in pulmonary artery smooth muscle cells. *Am J Physiol Lung Cell Mol Physiol.*
541 2006;291(5):L1059-67.
- 542 43. Witkowski SM, Noronha Ld, Okamoto CT, Oldenburg Neto CF, Almeida T, Nagashima S, et al.
543 Immunohistochemical analysis of apoptosis and cell proliferation in lungs of premature infants with
544 chronic lung disease (bronchopulmonary dysplasia). *J Bras Patol Med Lab.* 2016;52:407-15.
- 545 44. Husari AW, Dbaibo GS, Bitar H, Khayat A, Panjarian S, Nasser M, et al. Apoptosis and the
546 activity of ceramide, Bax and Bcl-2 in the lungs of neonatal rats exposed to limited and prolonged
547 hyperoxia. *Respir Res.* 2006;7(1):100.

548 45. Del Puerto HL, Martins AS, Moro L, Milsted A, Alves F, Braz GF, et al. Caspase-3/-8/-9, Bax
549 and Bcl-2 expression in the cerebellum, lymph nodes and leukocytes of dogs naturally infected with
550 canine distemper virus. *Genet Mol Res.* 2010;9(1):151-61.

551 46. Disatian S, Ehrhart EJ, Zimmerman S, Orton EC. Interstitial cells from dogs with naturally
552 occurring myxomatous mitral valve disease undergo phenotype transformation. *J Heart Valve Dis.*
553 2008;17(4):402-11.

554 47. Disatian S, Lacerda C, Orton EC. Tryptophan hydroxylase 1 expression is increased in
555 phenotype-altered canine and human degenerative myxomatous mitral valves. *J Heart Valve Dis.*
556 2010;19(1):71-8.

557 48. Keene BW, Atkins CE, Bonagura JD, Fox PR, Häggström J, Fuentes VL, et al. ACVIM consensus
558 guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. *J Vet Intern*
559 *Med.* 2019;33(3):1127-40.

560 49. Chen W, Lu C, Hirota C, Iacucci M, Ghosh S, Gui X. Smooth muscle hyperplasia/hypertrophy
561 is the most prominent histological change in Crohn's fibrostenosing bowel strictures: A
562 semiquantitative analysis by using a novel histological grading scheme. *J Crohns Colitis.*
563 2017;11(1):92-104.

564

Figures




Figure 1

The histopathology of the pulmonary artery Masson's trichrome staining revealed normal thin medial layer in the control group (a) and increased medial thickness in the degenerative mitral valve disease (DMVD) (b) and degenerative mitral valve disease with pulmonary hypertension (DMVD+PH) (c) groups. Red color are staining of SMCs; Blue color are staining of collagen fibers (Masson's trichrome stain, 100x magnification).




Figure 2

The percentage of medial thickness and the average number of pulmonary arterial SMCs per vessel. The graphs show the percentage of medial thickness (%MT) (a) and the average number of pulmonary arterial SMCs per vessel (b) of the control, degenerative mitral valve disease (DMVD) and degenerative

mitral valve disease with pulmonary hypertension (DMVD+PH) groups. Data are expressed as mean and standard deviation (SD) (bars). An increase in %MT in the DMVD and DMVD+PH groups conforms to an increase in the average number of pulmonary arterial SMCs. a Indicate statistically significant difference at $p < 0.05$ compared to the control group. b,c Indicate statistically significant difference at $p < 0.05$ between the DMVD and DMVD+PH groups.




Figure 3

Immunohistochemical expression of Bax and Bcl2 in pulmonary arteries. The images show the expression of Bax and Bcl2 in the pulmonary arteries of the control (a, d), degenerative mitral valve disease (DMVD) (b, e) and degenerative mitral valve disease with pulmonary hypertension (DMVD+PH) groups (c, f). These proteins were mainly expressed in SMCs located at medial layer of pulmonary artery. Bax protein was stained in all groups, whereas Bcl2 protein was not stained in the control group. The intracytoplasmic staining of Bax and intranuclear staining of Bcl2 in pulmonary arterial SMCs presented as brown color (Labeled streptavidin-biotin, Immunohistochemistry, Mayer's Hematoxylin counterstained, 400x magnification).




Figure 4

Immunohistochemical expression of caspase-3 and -8 in pulmonary arteries. The images show the expression of caspase-3 and -8 in the pulmonary arteries of the control (a, d), degenerative mitral valve disease (DMVD) (b, e) and degenerative mitral valve disease with pulmonary hypertension (DMVD+PH) groups (c, f). The caspase-3 and -8 expressions were mainly found in SMCs located at the medial layer of the pulmonary artery in all 3 groups. The intracytoplasmic and intranuclear staining of caspase-3 and intracytoplasmic staining of caspase-8 were in brown color. (Labeled streptavidin-biotin, Immunohistochemistry, Mayer's Hematoxylin counterstained, 400x magnification).




Figure 5

The percentage of Bax, Bcl2, and caspase-3 and -8 positive cells and Bax/Bcl2 ratio. The graph shows the percentage of Bax, Bcl2, and caspase-3 and -8 positive cells and Bax/Bcl2 ratio of the control, degenerative mitral valve disease (DMVD) and degenerative mitral valve disease with pulmonary hypertension (DMVD+PH) groups. Data are expressed as mean and standard deviation (SD) (bars). The percentage of Bax and caspase-3 and -8 positive cells as well as Bax/Bcl2 ratio were highest in the DMVD group, opposite to the percentage of Bcl2 positive cells that was highest in the DMVD+PH group. a indicates statistically significant difference at $p < 0.05$ compared to the control group. b,c indicate statistically significant difference at $p < 0.05$ between the DMVD and DMVD+PH groups.